Winnie Yeo

TL;DR: Durable objective responses show the potential of nivolumab for treatment of advanced hepatocellular carcinoma, and safety and tolerability for the escalation phase and objective response rate were primary endpoints.

TL;DR: The ALBI grade offers a simple, evidence-based, objective, and discriminatory method of assessing liver function in HCC that has been extensively tested in an international setting and eliminates the need for subjective variables such as ascites and encephalopathy, a requirement in the conventional C-P grade.

TL;DR: In patients with chronic HBV infection under chemotherapy, HBV reactivation occurs in nearly 20% of them and accounts for 44% of hepatitis cases; the risk factors identified include male sex, younger age, HBeAg seropositive, and the diagnosis of lymphoma.

TL;DR: Close monitoring until at least 6 months after anticancer therapy is required, with an alternative approach of prophylactic antiviral therapy to prevent this potentially fatal condition.

TL;DR: Although patients on PIAF had a higher overall response rate and better survival than patients on doxorubicin, the differences were not statistically significant and the prognosis of patients with unresectable HCC remains poor.